Robert J. Tomsich Pathology and Laboratory Medicine Institute.
Department of Pathology, Stanford Medical Center, Stanford, CA.
Am J Surg Pathol. 2023 Sep 1;47(9):1001-1010. doi: 10.1097/PAS.0000000000002079. Epub 2023 Jun 26.
The aim of this study was to assess the histopathologic spectrum of renal tumors in patients with PTEN hamartoma tumor syndrome (PHTS), with a specific focus on potential features predictive of the underlying syndrome. A multi-institutional study was conducted to obtain clinical and pathologic data on renal tumors arising in patients with PHTS, either diagnosed by germline mutational analysis or clinical criteria for Cowden syndrome. Histologic sections of the renal tumors were re-reviewed for classification. Twelve renal epithelial tumors from 9 patients were identified (4 males and 5 females, with a mean age of 41.8 y), 7 of whom carried germline PTEN mutations. All 12 renal epithelial tumors were renal cell carcinomas (RCCs): 5 were chromophobe RCCs, 4 papillary RCCs, and 3 RCC not otherwise specified. Pathologic stage distribution was: 7 (59%) pT1a, 2 (17%) pT1b, 1 (8%) pT2a, 1 (8%) pT2b, and 1 (8%) pT3a. World Health Organization/International Society of Urological Pathology (WHO/ISUP) histologic grade was applicable in 7 (54%) nonchromophobe tumors: 4 (57%) G2, 2 (29%) G3, and 1 (14%) G4. An unexpected histologic finding was the presence of 2 patients with incidental microscopic collections of intrarenal adipocytes that had no features of angiomyolipoma (and were negative with 2 sensitive PEComa markers: cathepsin-K and GPNMB); both were classified as lipoma/"lipomatous hamartomas." The average follow-up interval was 67.8 months (13 to 172 mo): 5 patients had no evidence of disease, 2 were lost to follow-up, 1 died of other (non-PHTS) causes (ie, prostate cancer), and 1 was alive with metastatic RCC to the lung (RCC not otherwise specified with rhabdoid differentiation). All tumors showed loss of nuclear PTEN staining by immunohistochemistry. Fumarate hydratase was retained and 2SC was negative in all papillary RCCs. CK7 was moderate-strong/diffuse positive in 4 of 5 chromophobe RCCs and in 3 of 4 papillary RCCs. Renal epithelial tumors associated with PHTS represent a heterogeneous group of RCCs, but classic chromophobe and papillary RCC are most common. The majority have a favorable clinical behavior as would be predicted by subtype. In contrast to other hereditary renal neoplasia syndromes, morphologic features of the RCCs do not allow identification of PHTS-associated neoplasia with any degree of specificity in the absence of clinical setting and/or prior history, but the presence of microscopic "lipomas" within the kidney may provide a clue in rare cases. Therefore, clinical suspicion and genetic counseling with germline testing remain necessary for identifying PHTS-associated RCC.
本研究旨在评估患有 PTEN 错构瘤肿瘤综合征(PHTS)患者的肾脏肿瘤的组织病理学谱,特别关注潜在的预测潜在综合征的特征。进行了一项多机构研究,以获取 PHTS 患者中发生的肾脏肿瘤的临床和病理数据,这些患者要么通过种系突变分析诊断,要么通过考登综合征的临床标准诊断。对肾脏肿瘤的组织学切片进行了重新审查以进行分类。在 9 名患者中发现了 12 个肾脏上皮性肿瘤(4 名男性和 5 名女性,平均年龄 41.8 岁),其中 7 名携带种系 PTEN 突变。所有 12 个肾脏上皮性肿瘤均为肾细胞癌(RCC):5 个为嫌色细胞 RCC,4 个为乳头状 RCC,3 个为未特指的 RCC。病理分期分布为:7 例(59%)为 pT1a,2 例(17%)为 pT1b,1 例(8%)为 pT2a,1 例(8%)为 pT2b,1 例(8%)为 pT3a。在 7 例(54%)非嫌色细胞瘤中,适用世界卫生组织/国际泌尿病理学会(WHO/ISUP)组织学分级:4 例(57%)为 G2,2 例(29%)为 G3,1 例(14%)为 G4。一个意外的组织学发现是,有 2 例患者存在肾内脂肪细胞的偶然显微镜下聚集,这些细胞没有血管平滑肌脂肪瘤的特征(并且对 2 种敏感的 PEComa 标志物:组织蛋白酶-K 和 GPNMB 均为阴性);两者均被归类为脂肪瘤/“脂肪瘤样错构瘤”。平均随访间隔为 67.8 个月(13 至 172 个月):5 例患者无疾病证据,2 例失访,1 例死于其他(非 PHTS)原因(即前列腺癌),1 例存活患有肺转移 RCC(未特指的 RCC 伴横纹肌样分化)。所有肿瘤的免疫组织化学染色均显示核 PTEN 染色缺失。所有乳头状 RCC 中均保留了延胡索酸水合酶,2SC 均为阴性。在 5 个嫌色细胞 RCC 中的 4 个和 4 个乳头状 RCC 中的 3 个中,CK7 为中度至强/弥漫阳性。与 PHTS 相关的肾脏上皮性肿瘤代表一组异质性的 RCC,但经典的嫌色细胞和乳头状 RCC最为常见。大多数具有良好的临床行为,这与亚型的预测相符。与其他遗传性肾脏肿瘤综合征不同,在没有临床背景和/或既往病史的情况下,RCC 的形态特征不能以任何程度的特异性识别 PHTS 相关肿瘤,但肾脏内存在微小的“脂肪瘤”可能在极少数情况下提供线索。因此,临床怀疑和遗传咨询与种系检测仍然是识别与 PHTS 相关的 RCC 所必需的。